Cargando…
Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients
BACKGROUND: In consideration of no standard exclusion criteria for hepatitis B virus (HBV) loads in hepatocellular carcinoma (HCC)-related clinical trials, this study aimed to investigate the prevalence of HBV-related exclusion criteria among current clinical trials and evaluate whether antiviral tr...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034869/ https://www.ncbi.nlm.nih.gov/pubmed/35469289 http://dx.doi.org/10.2147/JHC.S363123 |
_version_ | 1784693192824717312 |
---|---|
author | Hu, Zili Sun, Xuqi Mei, Jie Hu, Zhiwen Yang, Ziliang Hou, Jingyu Fu, Yizhen Wang, Xiaohui Chen, Minshan |
author_facet | Hu, Zili Sun, Xuqi Mei, Jie Hu, Zhiwen Yang, Ziliang Hou, Jingyu Fu, Yizhen Wang, Xiaohui Chen, Minshan |
author_sort | Hu, Zili |
collection | PubMed |
description | BACKGROUND: In consideration of no standard exclusion criteria for hepatitis B virus (HBV) loads in hepatocellular carcinoma (HCC)-related clinical trials, this study aimed to investigate the prevalence of HBV-related exclusion criteria among current clinical trials and evaluate whether antiviral treatments could eliminate the adverse effects from high HBV loads for HCC patients. METHODS: This is a retrospective study including 772 HCC clinical trials on ClinicalTrials.gov and 1784 HCC patients receiving antiviral treatment. The Kaplan–Meier (K-M) method was used to compare the progression-free survival (PFS) and overall survival (OS) between different groups, and Cox regression analyses were performed to validate possible risk factors on PFS and overall survival OS. RESULTS: Among 772 clinical trials, 58.3% did not adopt baseline HBV loads as exclusion criteria, 18.0% was 2000 IU/mL, and 10.5% was receiving antiviral therapy. We observed baseline HBV loads had no significant impact on PFS (p = 0.491, 0.155, 0.119, 0.788, 0.280, 0.683 respectively) and OS (p = 0.478, 0.741, 0.263, 0.039, 0.999, 0.581 respectively) in all patients or each treatment group including hepatectomy, radiofrequency ablation, interventional therapy, targeted drugs and anti-programmed cell death immunotherapy, except for the OS of interventional therapy group, where patients with high HBV loads had higher BCLC stage, serum AFP level and ALBI grade (p = 0.009, 0.015 and 0.003, respectively). CONCLUSION: Antiviral treatments could eliminate the adverse impacts of high HBV loads on the survival of HCC patients. Simplified eligibility criteria can be adopted for HCC patients with HBV infection where regular antiviral therapy should be enough. |
format | Online Article Text |
id | pubmed-9034869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-90348692022-04-24 Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients Hu, Zili Sun, Xuqi Mei, Jie Hu, Zhiwen Yang, Ziliang Hou, Jingyu Fu, Yizhen Wang, Xiaohui Chen, Minshan J Hepatocell Carcinoma Original Research BACKGROUND: In consideration of no standard exclusion criteria for hepatitis B virus (HBV) loads in hepatocellular carcinoma (HCC)-related clinical trials, this study aimed to investigate the prevalence of HBV-related exclusion criteria among current clinical trials and evaluate whether antiviral treatments could eliminate the adverse effects from high HBV loads for HCC patients. METHODS: This is a retrospective study including 772 HCC clinical trials on ClinicalTrials.gov and 1784 HCC patients receiving antiviral treatment. The Kaplan–Meier (K-M) method was used to compare the progression-free survival (PFS) and overall survival (OS) between different groups, and Cox regression analyses were performed to validate possible risk factors on PFS and overall survival OS. RESULTS: Among 772 clinical trials, 58.3% did not adopt baseline HBV loads as exclusion criteria, 18.0% was 2000 IU/mL, and 10.5% was receiving antiviral therapy. We observed baseline HBV loads had no significant impact on PFS (p = 0.491, 0.155, 0.119, 0.788, 0.280, 0.683 respectively) and OS (p = 0.478, 0.741, 0.263, 0.039, 0.999, 0.581 respectively) in all patients or each treatment group including hepatectomy, radiofrequency ablation, interventional therapy, targeted drugs and anti-programmed cell death immunotherapy, except for the OS of interventional therapy group, where patients with high HBV loads had higher BCLC stage, serum AFP level and ALBI grade (p = 0.009, 0.015 and 0.003, respectively). CONCLUSION: Antiviral treatments could eliminate the adverse impacts of high HBV loads on the survival of HCC patients. Simplified eligibility criteria can be adopted for HCC patients with HBV infection where regular antiviral therapy should be enough. Dove 2022-04-19 /pmc/articles/PMC9034869/ /pubmed/35469289 http://dx.doi.org/10.2147/JHC.S363123 Text en © 2022 Hu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Hu, Zili Sun, Xuqi Mei, Jie Hu, Zhiwen Yang, Ziliang Hou, Jingyu Fu, Yizhen Wang, Xiaohui Chen, Minshan Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients |
title | Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients |
title_full | Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients |
title_fullStr | Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients |
title_full_unstemmed | Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients |
title_short | Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients |
title_sort | antiviral treatments eliminate the adverse impacts of high baseline hbv loads on the survival of hbv-related hcc patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034869/ https://www.ncbi.nlm.nih.gov/pubmed/35469289 http://dx.doi.org/10.2147/JHC.S363123 |
work_keys_str_mv | AT huzili antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT sunxuqi antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT meijie antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT huzhiwen antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT yangziliang antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT houjingyu antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT fuyizhen antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT wangxiaohui antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients AT chenminshan antiviraltreatmentseliminatetheadverseimpactsofhighbaselinehbvloadsonthesurvivalofhbvrelatedhccpatients |